Literature DB >> 30571177

Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.

Zheng Wang1,2, Wei Hu3, Chenxi Lu1, Zhiqiang Ma4, Shuai Jiang5, Chunhu Gu6, Darío Acuña-Castroviejo7, Yang Yang1.   

Abstract

Inflammation is an important innate immune response to infection or tissue damage. Inflammasomes are involved in the onset and development of inflammation. The NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome is the best-characterized inflammasome. Recent evidence has indicated the importance of the NLRP3 inflammasome in the pathophysiology of cardiovascular disorders. To further understand the roles of the NLRP3 inflammasome in the cardiovascular system, we provide a comprehensive overview and discuss the remaining questions. First, a summary of NLRP3 inflammasome in the cardiovascular system is introduced. Then, the associations between NLRP3 inflammasome and cardiovascular disorders are presented. Finally, we discuss existing problems and potential directions with this issue. The information compiled here summarizes recent progress, thus potentially aiding in the understanding of the NLRP3 inflammasome in cardiovascular disorders, designing experimental and clinical research about the NLRP3 inflammasome, and promoting therapeutics for cardiovascular disorders.

Entities:  

Keywords:  atherosclerosis; cardiovascular diseases; inflammation; interleukins; myocardial ischemia

Mesh:

Substances:

Year:  2018        PMID: 30571177     DOI: 10.1161/ATVBAHA.118.311916

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

1.  Highlighting Residual Atherosclerotic Cardiovascular Disease Risk.

Authors:  Yunosuke Matsuura; Jenny E Kanter; Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

Review 2.  A Spotlight on the Underlying Activation Mechanisms of the NLRP3 Inflammasome and its Role in Atherosclerosis: A Review.

Authors:  Anam Liaqat; Muhammad Asad; Fatima Shoukat; Arif-Ullah Khan
Journal:  Inflammation       Date:  2020-12       Impact factor: 4.092

3.  NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation.

Authors:  Liudmila Andreeva; Liron David; Shaun Rawson; Chen Shen; Teerithveen Pasricha; Pablo Pelegrin; Hao Wu
Journal:  Cell       Date:  2021-12-02       Impact factor: 41.582

4.  Age and Chronodisruption in Mouse Heart: Effect of the NLRP3 Inflammasome and Melatonin Therapy.

Authors:  Marisol Fernández-Ortiz; Ramy K A Sayed; Yolanda Román-Montoya; María Ángeles Rol de Lama; José Fernández-Martínez; Yolanda Ramírez-Casas; Javier Florido-Ruiz; Iryna Rusanova; Germaine Escames; Darío Acuña-Castroviejo
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

Review 5.  CD38: A Potential Therapeutic Target in Cardiovascular Disease.

Authors:  Wanyun Zuo; Na Liu; Yunhong Zeng; Yaozhong Liu; Biao Li; Keke Wu; Yunbin Xiao; Qiming Liu
Journal:  Cardiovasc Drugs Ther       Date:  2021-08       Impact factor: 3.727

6.  α1-AR overactivation induces cardiac inflammation through NLRP3 inflammasome activation.

Authors:  Jun-Zhou Xin; Ji-Min Wu; Guo-Min Hu; Hui-Jun Gu; Ye-Nan Feng; Shuai-Xing Wang; Wen-Wen Cong; Ming-Zhe Li; Wen-Li Xu; Yao Song; Han Xiao; You-Yi Zhang; Li Wang
Journal:  Acta Pharmacol Sin       Date:  2019-09-17       Impact factor: 6.150

7.  MicroRNA-21 mediates the protective effects of salidroside against hypoxia/reoxygenation-induced myocardial oxidative stress and inflammatory response.

Authors:  Bing Liu; Huali Wei; Ming Lan; Na Jia; Junmeng Liu; Meng Zhang
Journal:  Exp Ther Med       Date:  2020-01-03       Impact factor: 2.447

Review 8.  The Role of NLRP3 Inflammasome in Cerebrovascular Diseases Pathology and Possible Therapeutic Targets.

Authors:  Rongrong Bai; Yue Lang; Jie Shao; Yu Deng; Reyisha Refuhati; Li Cui
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

Review 9.  Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis.

Authors:  Qi Chen; Jianjun Lv; Wenwen Yang; Baoping Xu; Zheng Wang; Zihao Yu; Jiawei Wu; Yang Yang; Yuehu Han
Journal:  Theranostics       Date:  2019-08-14       Impact factor: 11.556

Review 10.  Coptisine from Coptis chinensis exerts diverse beneficial properties: A concise review.

Authors:  Jiasi Wu; Yu Luo; Donghang Deng; Siyu Su; Sheng Li; Li Xiang; Yingfan Hu; Ping Wang; Xianli Meng
Journal:  J Cell Mol Med       Date:  2019-10-17       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.